Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019

This report updates the 2009 recommendations from the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) regarding use of anthrax vaccine in the United States. The report summarizes data on estimated efficacy in humans using a correlates of protection model and safety data and provides updated guidance for use of anthrax vaccine adsorbed for preexposure prophylaxis.

Shigella flexneri Adherence Factor Expression in In Vivo-Like Conditions

Despite significant gains in understanding of Shigella infection, it remains unknown how the bacteria initiate contact with the colonic epithelium. This research identified conditions that mimic some features of gastrointestinal transit and that enable Shigella to express adherence structural genes.

Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox

Researchers assigned 440 participants to receive two doses of MVA followed by one dose of the established replicating-vaccinia vaccine ACAM2000 (the MVA group) or to receive one dose of ACAM2000 (the ACAM2000-only group). No safety concerns associated with the MVA vaccine were identified, and immune responses and attenuation of the major cutaneous reaction suggest the MVA vaccine protected against variola infection. 

The Military Is Developing a Vaccine to Stop a Bioterrorism Agent

The US Government is funding a project to develop a vaccine for a pneumonia-like disease. The vaccine was effective in a one-month study with mice that found it prevented those treated from contracting melioidosis, a disease caused by contact with bacteria typically found in Puerto Rico, Southeast Asia, and Australia.